Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 19, 2014

Roche and Garvan Institute Deal Targets Epigenomic Analysis

  • Roche and the Garvan Institute of Medical Research said they will collaborate on the development of novel technologies for targeted epigenomic analysis using DNA sequencing. Under the terms of the two-year discovery agreement, the Garvan Institute and Roche will focus on new methods for accurately analyzing regions of the epigenome. The collaboration brings together the genomics expertise and infrastructure at the Garvan Institute and products for target enrichment from Roche NimbleGen, part of the Roche Sequencing Unit. The SeqCap Target Enrichment System from Roche will be used by scientists at the Garvan Institute to further their research in epigenetic influences on human diseases.

    "This is an excellent example of collaboration between a leading edge company and research institute in the development of advanced technology for genetic analysis, which will empower more research into human biology and disease, and lead to many translational opportunities," noted John Mattick, Ph.D., executive director of the Garvan Institute.

    "In addition to our recent investments in sequencing platform technologies, our research team is working closely with key opinion leaders to advance sequencing applications of current and future technologies," added Tom Albert, head of research at Roche's Sequencing Unit. "This collaboration with the Garvan Institute illustrates the potential of SeqCap Target Enrichment products in additional sequencing applications for epigenetic research. This brings us closer to delivering sequencing applications to the clinic that offer truly differentiated medical value."



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »